Betamethasone is given during pregnancy to speed up fetal lung development when a baby is at risk of being born too early. A fetus’s lungs are among the last organs to mature, and a premature infant whose lungs cannot produce enough surfactant, the slippery coating that keeps air sacs from collapsing, faces life-threatening breathing problems. A course of betamethasone, typically two injections into the mother’s muscle, triggers the fetal lungs to ramp up surfactant production days or even weeks ahead of schedule. The treatment has been one of the most significant advances in neonatal medicine, but its benefits, timing, and limitations are more nuanced than a simple “steroid shot for the lungs” suggests.
How Betamethasone Reaches and Matures the Fetal Lungs
After an intramuscular injection, betamethasone crosses the placenta efficiently. Studies measuring drug levels in maternal blood, umbilical cord blood, and amniotic fluid have found similar concentrations across all three compartments in the days following treatment.1PubMed. Placental transfer and metabolism of betamethasone in human pregnancy That placental permeability is the whole point: the drug needs to reach the fetus in concentrations high enough to act on developing lung tissue.
Once it arrives, betamethasone works on several fronts simultaneously. It stimulates the type II cells lining the fetal air sacs to produce more surfactant phospholipids, the fatty molecules that lower surface tension and prevent alveoli from sticking shut during exhalation. It also boosts the activity of enzymes involved in making those phospholipids and increases expression of surfactant-associated proteins.2PubMed. Corticosteroids and surfactant for prevention of neonatal RDS Animal studies have confirmed that betamethasone-treated fetuses show significantly higher levels of surfactant proteins SP-A, SP-B, and SP-C, bringing preterm lung tissue closer to the profile seen in full-term lungs.3PubMed Central. Antenatal Betamethasone Induces Increased Surfactant Proteins and Decreased Foxm1 Expressions in Fetal Rabbit Pups
Beyond surfactant chemistry, betamethasone accelerates the structural maturation of lung architecture itself. In preterm lamb studies, corticosteroid exposure led to thinning of alveolar walls and larger average alveolar volumes, changes that correlated with measurably better lung function after delivery.4Pediatric Research. Maternal and Intra-amniotic Corticosteroid Effects on Lung Morphometry in Preterm Lambs In rhesus monkeys, betamethasone accelerated the recruitment of new alveoli per gram of lung tissue, though it also slightly reduced overall lung weight, suggesting the drug trades raw growth for functional readiness.5American Review of Respiratory Disease. Influence of Betamethasone on the Development of Mechanical Properties in the Fetal Rhesus Monkey Lung The net result is a lung that, while not fully mature, can handle the transition to breathing air far better than it otherwise would.
When It Is Given and How Timing Matters
The standard course is two intramuscular doses of 12 mg each, separated by either 12 or 24 hours. Trials have compared both intervals and found similar outcomes, so clinical practice varies by institution.6American Journal of Obstetrics & Gynecology. Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial The classic target population is women between about 23 and 34 weeks of gestation who are considered at high risk of delivering within the next seven days, whether because of preterm labor, preterm rupture of membranes, or a planned early delivery for medical reasons.
Timing relative to delivery turns out to be critical. A large 2025 analysis found that the reduction in neonatal mortality associated with the treatment reached a plateau around 12 hours after the first dose, and the optimal window ran from 12 hours to 14 days before birth.7JAMA Network Open. Timing of Antenatal Corticosteroid Administration and Neonatal Outcomes Babies born within just a few hours of the first injection may not have had enough time to benefit fully, while babies who remain in utero for weeks afterward may see the initial effects begin to wane. Research on drug levels in cord blood supports this: the longer the time between the last dose and delivery with undetectable betamethasone levels, the higher the odds of respiratory distress syndrome in the newborn.8PubMed. Maternal Betamethasone for Prevention of Respiratory Distress Syndrome in Neonates: Population Pharmacokinetic and Pharmacodynamic Approach
Benefits Beyond Breathing
While lung maturation gets most of the attention, betamethasone also reduces other serious complications of prematurity. One of the best-documented additional benefits is a lower rate of intraventricular hemorrhage, the bleeding inside the brain that can cause lasting neurological damage in very premature infants. In a study of infants born at 26 to 31 weeks, betamethasone exposure was associated with dramatically lower adjusted odds of both respiratory distress syndrome and intraventricular hemorrhage.9PubMed. The effect of corticosteroid therapy in the very premature infant More recent data suggest that these protective effects against brain hemorrhage may fade as time passes after the first course, but that retreatment can restore the benefit for infants at high risk of extremely early delivery.10PubMed. Betamethasone treatment-to-delivery interval, retreatment, and severe intraventricular hemorrhage in infants <28 weeks’ gestation
In multifetal pregnancies, which carry a higher baseline risk of preterm delivery, betamethasone has been shown to significantly reduce both the incidence of respiratory distress syndrome and the need for ventilator support.11PubMed Central. Prenatal Administration of Betamethasone and Neonatal Respiratory Distress Syndrome in Multifetal Pregnancies: A Randomized Controlled Trial That said, the evidence in twins and higher-order multiples is less straightforward than in singletons, with ongoing debate about whether the standard dosing works as well when the drug must cross more than one placenta or reach fetuses with different growth patterns.12PubMed Central. The role of antenatal corticosteroids in twin pregnancy
The Late Preterm Question
Whether to give betamethasone at 34 to 36 weeks, the so-called late preterm period, is one of the more contested questions in obstetric practice. A major multicenter trial enrolled women with singleton pregnancies at 34 weeks 0 days through 36 weeks 5 days who were at high risk of delivering soon and found that betamethasone reduced neonatal respiratory complications.13PubMed Central. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery On the strength of that trial, many guidelines now support the option of late preterm treatment in select patients.
But the picture is not uniformly positive. A separate study of late preterm neonates found that those whose mothers received betamethasone actually had higher rates of respiratory distress and needed more respiratory support than controls.14PubMed Central. The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation Another study reached the opposite conclusion, reporting that betamethasone at 34 to 37 weeks improved respiratory outcomes and reduced NICU admissions.15PubMed. Evaluation of the effect of antenatal betamethasone on neonatal respiratory morbidities in late preterm deliveries (34-37 weeks) The disagreement likely reflects differences in patient selection, timing of delivery after treatment, and the availability of neonatal support. At these later gestational ages, the potential benefit is smaller because the lungs are already fairly mature, which means the risk-benefit calculation is more finely balanced than at earlier weeks.
Repeat Courses and Their Trade-Offs
When a woman remains pregnant a week or more after her first course, clinicians face the question of whether to give another round. A large individual-participant meta-analysis of repeat prenatal corticosteroids found a modest but real reduction in the need for respiratory support, though it also documented a small decrease in birth weight z-scores.16PLOS Medicine. Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis An earlier study found that repeated weekly courses offered no additional survival benefit in singletons born at or after 27 weeks or in multiples born at or after 26 weeks, and noted smaller head circumferences in some repetitively treated singletons.17PubMed. Single versus repeated-course antenatal corticosteroids: outcomes in singleton and multiple-gestation pregnancies
The long-term safety picture for repeat courses has been cautiously reassuring. One trial that followed children to age two to three found no significant differences in developmental scores or body size between those exposed to weekly repeat betamethasone and those given placebo after the initial course. However, the repeat-course group did show a numerically higher rate of cerebral palsy, about 2.9% of pregnancies versus 0.5% in the placebo group, a difference that did not reach statistical significance but has kept researchers watchful.18PubMed. Long-term outcomes after repeat doses of antenatal corticosteroids Current practice generally limits repeat treatment to a single “rescue” course rather than unlimited weekly rounds, a compromise between preserving the respiratory benefit and minimizing cumulative steroid exposure.
Temporary Effects on the Fetus During Treatment
If you are on a fetal monitor around the time betamethasone is given, the tracing can look alarming. Studies consistently show that within a day or two of administration, fetal heart rate baseline rises, variability drops, and the number of accelerations decreases.19PubMed. Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study Fetal breathing movements and body movements also decrease, and the fetus may spend longer stretches in quiet states.20PubMed. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial These changes typically return to baseline by the third or fourth day after treatment.
Interestingly, the behavioral effects depend on how far along the pregnancy is. In fetuses between 29 and 34 weeks, betamethasone caused noticeable drops in heart rate, breathing activity, and body movements. But in younger fetuses at 26 to 28 weeks, some of these changes were absent, likely because the neural circuits mediating those responses are not yet fully wired.21PubMed. The effects of antenatal betamethasone administration on fetal heart rate and behaviour depend on gestational age The practical takeaway is that clinicians who know betamethasone was recently given can interpret a temporarily worrying fetal heart rate pattern in context rather than rushing to intervene.
Maternal Side Effects Worth Knowing About
Betamethasone is a potent glucocorticoid, and one of its most predictable effects in the mother is a temporary spike in blood sugar. For women with gestational diabetes, this can require significant adjustments to insulin dosing. Research has shown that insulin needs rise in step with each betamethasone dose, and in women previously managed on diet alone, the steroid can push blood sugar high enough to require temporary insulin therapy.22PubMed. Glycemic profile assessment during betamethasone administration in women with gestational diabetes mellitus Hospitals have developed pregnancy-specific insulin protocols for this scenario, which have been shown to keep blood sugar on target more reliably and reduce neonatal hypoglycemia compared to standard adult insulin regimens.23PubMed. An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes
Because corticosteroids can suppress the immune system, there has been long-standing concern about whether betamethasone leaves pregnant women vulnerable to infection. The evidence is broadly reassuring. White blood cell counts do jump, with one study documenting a roughly 33% increase in total white cells on the first day after injection, driven by a rise in neutrophils and a drop in lymphocytes, all returning to baseline by day three.24PubMed. The effect of betamethasone administration to pregnant women on maternal serum indicators of infection Those lab shifts can mimic early infection and confuse clinicians watching for signs of chorioamnionitis. But functional immune testing has found that the suppression of T-cell responses is transient and incomplete, lasting under 72 hours, and that the ability of maternal immune cells to actually kill intracellular bacteria remained intact after betamethasone exposure.25American Journal of Obstetrics and Gynecology. The effects of betamethasone on maternal cellular resistance to infection The temporary lab changes are worth knowing about so they are not mistaken for a new infection, but they do not represent a meaningful breach in immune defense.
Betamethasone Versus Dexamethasone
Dexamethasone is the other corticosteroid commonly used for fetal lung maturation, and the two drugs are closely related chemically. A network meta-analysis comparing them head-to-head found no meaningful clinical or statistical difference in neonatal death, neurodevelopmental disability, intraventricular hemorrhage, or birth weight.26American Journal of Obstetrics & Gynecology MFM. Corticosteroids for preterm birth: a network meta-analysis Why, then, do some institutions prefer one over the other? Part of the answer is formulation. Betamethasone is often given as a mixture of a fast-acting phosphate ester and a slower-release acetate suspension, which sustains drug levels longer with fewer injections. Dexamethasone is typically given as four doses over 48 hours. Regional availability and cost also play a role. In practice, either drug works, and the choice often comes down to what is on the shelf.
Long-Term Safety for the Child
Parents naturally worry about whether exposing a fetus to a powerful steroid has lasting consequences. The follow-up data so far are largely reassuring. A study tracking children to school age after exposure to repeated courses of betamethasone found no evidence of increased disability or neurocognitive differences, whether or not the child had experienced fetal growth restriction.27PubMed Central. Association of Fetal Growth Restriction With Neurocognitive Function After Repeated Antenatal Betamethasone Treatment vs Placebo A separate study specifically evaluating children whose mothers received betamethasone to prevent congenital heart block (a different indication) also found no negative effects on long-term physical or neurodevelopmental outcomes.28The Journal of Maternal-Fetal & Neonatal Medicine. Long-term physical and neurodevelopmental outcomes after antenatal betamethasone administration for congenital heart block prevention
That said, most long-term studies have followed children only through early to mid-childhood. Whether there are subtler metabolic or cardiovascular effects that emerge later in life, an area of active research for all prenatal corticosteroid exposure, is not yet settled. The current consensus is that a single course carries no demonstrated long-term harm, and the short-term benefits for very preterm infants are substantial enough to justify the treatment. The caution around repeat courses, as discussed earlier, reflects a more uncertain trade-off.
Access Gaps in Low-Resource Settings
Betamethasone’s benefit depends heavily on the neonatal care infrastructure that catches the baby after delivery. In high-income countries with well-equipped NICUs, the treatment is routine and its benefits are well established. In low- and middle-income countries, where most of the world’s preterm births occur, the picture is more complicated. A scoping review found that antenatal corticosteroids reduced neonatal mortality and respiratory distress in hospitals with high levels of neonatal care, but that the benefit was inconsistent in lower-resource settings.29PubMed. Reducing neonatal mortality and respiratory distress syndrome associated with preterm birth: a scoping review on the impact of antenatal corticosteroids in low- and middle-income countries
The reasons are practical. If a facility cannot reliably provide respiratory support, monitor blood sugar, or manage infections in a premature newborn, giving the steroid may expose the mother to side effects without a corresponding payoff for the baby. A recent multi-country assessment found that across eight low- and middle-income countries, only about one in ten facilities had actually provided antenatal corticosteroids, and only about a quarter had injectable corticosteroids in stock at the time of the survey.30PubMed Central. Antenatal corticosteroids for pregnant women at risk of preterm labour in low- and middle-income countries: utilisation and facility readiness The World Health Organization now recommends that the treatment be given only at facilities that meet minimum readiness criteria, including the ability to accurately assess gestational age, manage preterm labor, and provide newborn care. Expanding access to the drug without expanding the surrounding care infrastructure does not reliably save lives and can potentially cause harm.
How Drug Levels Connect to Outcomes
One area of growing research interest is the relationship between actual betamethasone concentrations in the newborn’s blood and clinical outcomes. Rather than treating corticosteroid exposure as a binary (received it or did not), researchers have started measuring neonatal serum levels at birth. A prospective cohort study found that higher betamethasone levels at delivery were associated with a lower risk of respiratory distress syndrome, and identified a specific threshold that predicted RDS with reasonable accuracy.31PubMed Central. Association between betamethasone levels and respiratory distress syndrome in preterm births: A prospective cohort study This kind of pharmacokinetic data could eventually lead to more individualized dosing, where the amount and timing of betamethasone are adjusted based on maternal metabolism, fetal weight, and expected delivery timing rather than the one-size-fits-all two-dose protocol used now.
The formulation of the injection matters here too. The standard product used in many countries is a combination of betamethasone phosphate, which is absorbed quickly, and betamethasone acetate, a suspension that releases the drug more slowly. Pharmacokinetic studies in pregnant women have shown that the phosphate component reaches the bloodstream rapidly and almost completely, while the acetate component is absorbed much more gradually and never appears as intact acetate in plasma, instead releasing free betamethasone over time.32PubMed Central. Disposition of betamethasone in parturient women after intramuscular administration That two-phase release is part of what sustains fetal drug levels long enough for the lungs to respond, and it explains why a single injection can have effects lasting days rather than hours.